Scholars Central

Mini reviewPublished 28 Jul 2022

Induction or Exacerbation of Psoriatic Lesions During Anti-TNF- andalpha; Therapy

Authors: Eiichi Morii

Journal of Inflammatory Bowel Diseases & Disorders

Volume 7 · Issue 4 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti-TNF therapy. Paradoxical cases of psoriatic lesions induced or exacerbated by anti-tumor necrosis factor (TNF)-α therapy have been reported more frequently in recent years, but data related to inflammatory bowel disease (IBD) are rare. A systematic literature review was performed to provide information about this adverse effect in patients with IBD who receive anti- TNF therapy. In the last few years, tumor necrosis factor-alpha (TNF-α) antagonists such as infliximab and adalimumab have revolutionized the treatment of inflammatory bowel disease (IBD) and psoriasis.2However, as the use of these biologic agents has increased, reactivation of latent infections, cutaneous reactions (eczematous, neoplastic, granulomatous, and psoriatic lesions), and other side effects have been documented.

Keywords

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Inflammatory Bowel Diseases & Disorders
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Eiichi Morii”